Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis

EN. De Toni, A. Ziesch, A. Rizzani, HP. Török, S. Hocke, S. Lü, SC. Wang, T. Hucl, B. Göke, C. Bruns, E. Gallmeier,

. 2016 ; 7 (8) : 9477-90.

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc17014117

PURPOSE: DNA repair defects due to detrimental BRCA2-mutations confer increased susceptibility towards DNA interstrand-crosslinking (ICL) agents and define patient subpopulations for individualized genotype-based cancer therapy. However, due to the side effects of these drugs, there is a need to identify additional agents, which could be used alone or in combination with ICL-agents. Therefore, we investigated whether BRCA2-mutations might also increase the sensitivity towards TRAIL-receptors (TRAIL-R)-targeting compounds. EXPERIMENTAL DESIGN: Two independent model systems were applied: a BRCA2 gene knockout and a BRCA2 gene complementation model. The effects of TRAIL-R-targeting compounds and ICL-agents on cell viability, apoptosis and cell cycle distribution were compared in BRCA2-proficient versus-deficient cancer cells in vitro. In addition, the effects of the TRAIL-R2-targeting antibody LBY135 were assessed in vivo using a murine tumor xenograft model. RESULTS: BRCA2-deficient cancer cells displayed an increased sensitivity towards TRAIL-R-targeting agents. These effects exceeded and were mechanistically distinguishable from the well-established effects of ICL-agents. In vitro, ICL-agents expectedly induced an early cell cycle arrest followed by delayed apoptosis, whereas TRAIL-R-targeting compounds caused early apoptosis without prior cell cycle arrest. In vivo, treatment with LBY135 significantly reduced the tumor growth of BRCA2-deficient cancer cells in a xenograft model. CONCLUSIONS: BRCA2 mutations strongly increase the in vitro- and in vivo-sensitivity of cancer cells towards TRAIL-R-mediated apoptosis. This effect is mechanistically distinguishable from the well-established ICL-hypersensitivity of BRCA2-deficient cells. Our study thus defines a new genetic subpopulation of cancers susceptible towards TRAIL-R-targeting compounds, which could facilitate novel therapeutic approaches for patients with BRCA2-deficient tumors.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17014117
003      
CZ-PrNML
005      
20170427102033.0
007      
ta
008      
170413s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.18632/oncotarget.7053 $2 doi
035    __
$a (PubMed)26843614
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a De Toni, Enrico N $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
245    10
$a Inactivation of BRCA2 in human cancer cells identifies a subset of tumors with enhanced sensitivity towards death receptor-mediated apoptosis / $c EN. De Toni, A. Ziesch, A. Rizzani, HP. Török, S. Hocke, S. Lü, SC. Wang, T. Hucl, B. Göke, C. Bruns, E. Gallmeier,
520    9_
$a PURPOSE: DNA repair defects due to detrimental BRCA2-mutations confer increased susceptibility towards DNA interstrand-crosslinking (ICL) agents and define patient subpopulations for individualized genotype-based cancer therapy. However, due to the side effects of these drugs, there is a need to identify additional agents, which could be used alone or in combination with ICL-agents. Therefore, we investigated whether BRCA2-mutations might also increase the sensitivity towards TRAIL-receptors (TRAIL-R)-targeting compounds. EXPERIMENTAL DESIGN: Two independent model systems were applied: a BRCA2 gene knockout and a BRCA2 gene complementation model. The effects of TRAIL-R-targeting compounds and ICL-agents on cell viability, apoptosis and cell cycle distribution were compared in BRCA2-proficient versus-deficient cancer cells in vitro. In addition, the effects of the TRAIL-R2-targeting antibody LBY135 were assessed in vivo using a murine tumor xenograft model. RESULTS: BRCA2-deficient cancer cells displayed an increased sensitivity towards TRAIL-R-targeting agents. These effects exceeded and were mechanistically distinguishable from the well-established effects of ICL-agents. In vitro, ICL-agents expectedly induced an early cell cycle arrest followed by delayed apoptosis, whereas TRAIL-R-targeting compounds caused early apoptosis without prior cell cycle arrest. In vivo, treatment with LBY135 significantly reduced the tumor growth of BRCA2-deficient cancer cells in a xenograft model. CONCLUSIONS: BRCA2 mutations strongly increase the in vitro- and in vivo-sensitivity of cancer cells towards TRAIL-R-mediated apoptosis. This effect is mechanistically distinguishable from the well-established ICL-hypersensitivity of BRCA2-deficient cells. Our study thus defines a new genetic subpopulation of cancers susceptible towards TRAIL-R-targeting compounds, which could facilitate novel therapeutic approaches for patients with BRCA2-deficient tumors.
650    _2
$a zvířata $7 D000818
650    _2
$a myší monoklonální protilátky $x farmakologie $7 D058846
650    _2
$a protinádorové látky $x farmakologie $7 D000970
650    _2
$a apoptóza $x účinky léků $7 D017209
650    _2
$a protein BRCA2 $x genetika $7 D024682
650    _2
$a kontrolní body buněčného cyklu $x účinky léků $7 D059447
650    _2
$a nádorové buněčné linie $7 D045744
650    _2
$a proliferace buněk $7 D049109
650    _2
$a viabilita buněk $x účinky léků $7 D002470
650    _2
$a reagencia zkříženě vázaná $x farmakologie $7 D003432
650    _2
$a oprava DNA $x genetika $7 D004260
650    _2
$a lidé $7 D006801
650    _2
$a myši $7 D051379
650    _2
$a RNA interference $7 D034622
650    _2
$a malá interferující RNA $x genetika $7 D034741
650    _2
$a TRAIL receptory $x antagonisté a inhibitory $7 D053220
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Ziesch, Andreas $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Rizzani, Antonia $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Török, Helga-Paula $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Hocke, Sandra $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Lü, Shuai $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Wang, Shao-Chun $u Department of Cancer Biology, University of Cincinnati, Cincinnati, Ohio 45267, USA.
700    1_
$a Hucl, Tomas $u Department of Gastroenterology and Hepatology, University of Prague, 14021 Prague 4, Czech Republic.
700    1_
$a Göke, Burkhard $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany.
700    1_
$a Bruns, Christiane $u Department of Surgery, University of Magdeburg, 39120 Magdeburg, Germany.
700    1_
$a Gallmeier, Eike $u Department of Medicine II, Ludwig-Maximilians-University, 81377 Munich, Germany. Department of Gastroenterology, Philipps University Marburg, 35043 Marburg, Germany.
773    0_
$w MED00184852 $t Oncotarget $x 1949-2553 $g Roč. 7, č. 8 (2016), s. 9477-90
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26843614 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170413 $b ABA008
991    __
$a 20170427102353 $b ABA008
999    __
$a ok $b bmc $g 1200582 $s 974895
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 7 $c 8 $d 9477-90 $i 1949-2553 $m Oncotarget $n Oncotarget $x MED00184852
LZP    __
$a Pubmed-20170413

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace